


HEALTH BENEFITS FROM ACTIVE MOBILITY: EFFECT ON PRICING AND DESIGN OF PUBLIC TRANSPORT SERVICES




Lyon AFET 19 nov, 2025

Stef Proost

Stef.Proost@kuleuven.be

Research collaboration with Kenneth Rødseth (TOI Norway), Alejandro Tirachini and Paal Wangsness (TOI Norway)

QUESTIONS



1. Are there quantifiable health benefits from active mobility?
 - Are these benefits internal or external?
2. If so, what is the effect of these health benefits on the optimal design of transport systems:
 - a) Prices and subsidies
 - Walking
 - Cycling (private bikes and shared bikes)
 - Public transport
 - Cars
 - b) Public transport design: frequency of service, distance between bus stops or stations

HEALTH BENEFITS FROM ACTIVE MOBILITY

1. Health benefits from physical activity
 - Reduced mortality
 - Reduced probability of coronary heart disease, stroke, hypertension, diabetes, colon and breast cancer.
 - Improved mental health
2. For a person that cycles 5 km (one day), 5 days a week, 46 weeks a year, for 40 years: average life expectancy gain is 1.2 years (Rabl and de Nazelle, 2012)
 - Average value of a life year (VOLY): **43800 euros**
 - Health benefit monetised as 1300 euros per year
 - Result: health benefit monetised as **0.56 euro/km of cycling**
3. In case of serious illness, there are real economic costs as well: **healthcare costs and production losses**, which are also quantified (Statens Vegvesen, 2021)



<https://transportation.ucla.edu/blog/biking-your-way-better-health>

Rabl, A., de Nazelle, A. (2012) Benefits of shift from car to active transport. *Transport Policy* 19(1), 121-131.

Statens Vegvesen (2021) Konsekvensanalyser. V712 i Statens vegvesens håndbokserie

INCLUSION OF HEALTH BENEFITS IN POLICY SETTING?

- If active mobility has positive externalities due to health benefits, welfare economics theory would suggest that walking or cycling should be subsidized as a first-best policy.
- In practice, there are indeed some cases around the world of policies that directly or indirectly subsidize cycling
 - **Belgium**: subsidy of up to 0,27 €/km for commuting by bicycle, car commuting can receive a 0.15 €/km subsidy and public transport is usually for free for commuters.
 - **The Netherlands**: commuting subsidy up to 0.23 €/km, regardless if the person travels to work by walking, bicycle, public transport or private car.
 - **Colombia**: public servants have the right to a half day free of work every 30 days that they commute by bicycle.
 - **Norway, France, Germany, the Netherlands, Portugal, Spain, etc**: subsidies acquisition electric bicycles, either for personal mobility or for freight transport.
 - **HOWEVER**, In most of these cases, the bike subsidies are motivated by (efficient?) modal choice away from congested car use

Question: are these optimal or reasonable levels of subsidy for active mobility, in multimodal context in which active mobility competes with motorized modes?

HEALTH BENEFITS: INTERNAL OR EXTERNAL?

- Survey in Stockholm: 52% of cyclist state that exercise was the most important reason to choose cycling (Börjesson and Eliasson, 2012)
- If travelers consider the health effects when making travel decisions (Börjesson and Eliasson, 2012)
 - **Health benefits will be in consumer surplus** – both as increased demand for cycling and as a lower value of cycling time.
 - Adding health benefits to CBA would be (partially) double-counting.
 - In spite of this, some exercises consider 100% health benefits as external in CBA, e.g., Standen *et al.* (2019)
- However, **reduced healthcare cost and production loss are external**.

- Börjesson, M., & Eliasson, J. (2012). The value of time and external benefits in bicycle appraisal. *Transportation Research Part A: policy and practice*, 46(4), 673-683.
- Standen, C., Greaves, S., Collins, A. T., Crane, M., & Rissel, C. (2019). The value of slow travel: Economic appraisal of cycling projects using the logsum measure of consumer surplus. *Transportation Research Part A* 123, 255-268.

HEALTH BENEFITS FROM ACTIVE MOBILITY

Table 5-21 Reduced healthcare costs for new pedestrians and cyclists (2020-kr) (Norwegian Directorate of Health 2014 and 2017)¹⁴.

Reduced costs	Kr/km
Short-term sick leave for pedestrians	3,55
Short-term sick leave for cyclists	1,83
Serious illness for pedestrians (real economic costs (healthcare costs and production losses) + the welfare effect)	23,17
Serious illness for cyclists (real economic costs (healthcare costs and production losses) + the welfare effect)	14,67

- The health effect depends on the activity level already present in the population, and the intensity and duration of the activities.
- As there is no information on trip lengths for individual users, calculations are based on changes in total active travel distance.
- Estimated health benefits should not be used for minor route changes (length or intensity) for those already walking or cycling.

1 NOK = 0,085 Euro

MULTIMODAL TRANSPORT PLANNING AND PRICING FOR GIVEN LOCATIONS

Social Welfare(SW) = Users benefit + Surplus transport providers + Health Benefits – External Costs

(1)

(2)

(3)

(4)

- q_a : car demand
- q_b : bicycle demand
- q_w : walking demand
- q_{bs} : bike-sharing demand
- q_{pt-i} : public transport demand, multi modal access by $i \in \{w, b, bs\}$

- Active mode have health benefits, modelled in a per-km basis

MULTIMODAL TRANSPORT PLANNING AND PRICING

Social Welfare(SW) = Users benefit + Profit transport providers + Health Benefits – External Costs

(1)

(2)

(3)

(4)

SW

$$\begin{aligned} &= B(q_a, q_b, q_w, q_{bs}, q_{pt-w}, q_{pt-b}, q_{pt-bs}) - q_a c_a \\ &- q_w [c_w - l_w H_w] - q_b [c_b - l_b H_b] - q_{bs} [c_{bs} - l_{bs} H_{bs}] - q_{pt-bs} [c_{pt-bs} - l_{pt-bs}^a H_{bs}] - q_{pt-w} [c_{pt-w} - l_{pt-w}^a H_w] \end{aligned}$$

$$c_a = c_a(q_a, q_{pt}, f_{pt}, K_{pt}, S_{pt})$$

$$c_{pt} = c_{pt}(q_a, q_{pt}, f_{pt}, K_{pt}, S_{pt})$$

$$c_{bs} = c_{bs}(q_{bs})$$

- q_a : car demand
- q_b : bicycle demand
- q_w : walking demand
- q_{bs} : bike-sharing demand
- q_{pt-i} : public transport demand, access by $i \in \{w, b, bs\}$

MULTIMODAL TRANSPORT PLANNING AND PRICING

Social Welfare(SW) = Users benefit + Profit transport providers + Health Benefits – External Costs

(1)

Optimal first-best solution: prices τ

Cars

$$\tau_a = q_a \frac{\partial c_a}{\partial q_a}$$

Public transport

$$\tau_{pt} = c_{pt}^o + q_{pt} \frac{\partial c_{pt}}{\partial q_{pt}} - l_{pt}^a H_{acc}$$

Bicycles

$$\tau_b = -l_b H_b$$


Walking

$$\tau_w = -l_w H_w$$

(2)

(3)

(4)



- q_i : demand mode i
- c_i : cost mode i
- c_{pt}^o : operator cost bus
- l_i : trip length mode i
- H_i : monetized health benefits mode i

Marginal Operator cost + external crowding cost
- Health benefit

MULTIMODAL TRANSPORT PLANNING AND PRICING

Social Welfare(SW) = Users benefit + Profit transport providers + Health Benefits – External Costs

(1)

Optimal number of bus stops

- Increases with bus route length
- Decreases with the health benefits of walking H_{acc}
- Increases with total patronage
- decreases with frequency

(2)

Optimal bus frequency

- Increases with discomfort
- Increases with waiting time
- Decreases with bus costs

- q_i : demand mode i
- l_i : trip length mode i
- H_i : monetized health benefits mode i

(3)

(4)

Optimal number of bus stops

$$S_{pt} = \sqrt{\frac{\frac{P_a L}{2v_w} - q_b H_{acc} \frac{L}{2}}{c_1 f_b \frac{t_s}{q_b} + P_v \frac{l_b}{L} t_s + \frac{c_2}{q_b}}}$$

- P_a : Value access time savings
- P_v : Value in-vehicle time savings
- v_w : walking speed
- f_b : service frequency
- t_s : boarding/alighting time
- L : bus route length
- c_1, c_2 : unit operator costs bus

APPLICATION: OPTIMISATION BUS LINE OSLO

- Modal choice: bus, car, bicycle, walk
- Demand choice calibrated for Oslo
- PT supply: bus line 37 (18 km)
- Environmental externalities and health benefits from active mobility as monetised in Norway
- Optimisation (Max SW)
 - Bus frequency
 - Bus size
 - Bus stop spacing
 - Bus fare
 - Pricing alternative modes



bus 37 Nydalen T - Helsfyr

moovit



HEALTH BENEFITS AND EXTERNAL COSTS

1 NOK = 0,085 Euro

Table 3: Unit values for external costs and health benefits and avg. trip lengths of active modes of transport

Parameter	Car	Public transport	Cycle	Walk
<i>Avg. distance of active transport per trip (km)</i>	0.0	Endogenous	4.3	1.4
<i>Monetised benefits, S1 (NOK/km)</i>	0.0	10.8	4.6	10.8
<i>Monetised benefits, S2 (NOK/km)</i>	0.0	26.7	16.5	26.7
<i>External costs (NOK/km)</i>	1.2	3.5	0	0

S1 = reduction of health car costs and production losses

S2 = maximal interpretation, including Health benefits mostly internalised

1 NOK = 0,085 Euro

RESULTS 1 FIRST BEST

S0 = No
H benefits S1 = with
H benefits S2 = max
H benefits

BUS

Table 4: Characteristics of the no. 37 bus service in the benchmark equilibrium and first best scenarios S0-S2

	Benchmark	S0	S1	S2	
Capacity	110	110	110	110	
Frequency	12	18	18	17	← BUS features Higher frequency in first best
Pax/bus (no)	48	40	39	38	
Stops (no)	68	66	40	39	← Less bus stops
Access dist. (m)	408	415	615	618	

Table 5: Current and optimal prices (NOK₂₀₂₀) for transport per trip

PRICES	Benchmark	S0	S1	S2	PRICES
Car	23.0	42.7	41.8	38.9	Higher car tolls in optimum S0 without Health benefits (corridor dependent)
Bus	13.0	5.6	-1.5	-1.6	But no higher tolls from S0 to S1
Cycle	0.0	0.0	-19.6	-71.0	
Walk	0.0	0.0	-15.1	-37.4	Subsidized bus, cycle and walk

RESULTS 1ST BEST

Market shares do not change much: mainly less car use

Table 6: Market shares (trips) in the benchmark and first best scenarios S0-S2

	Benchmark	S0	S1	S2
Car	27	23	21	20
Bus	43	50	48	40
Cycle	5	5	7	12
Walk	25	22	24	28

Welfare +2%

	Benchmark	S0	S1	S2
Welfare	3 002	3 117	3 176	3 272
Consumer surplus	3 048	3 169	3 156	3 118
Operator profit	23	-5	-31	-29
External costs	26	25	25	24
Health benefits	0	0	63	222
Active transport subsidy	0	0	-43	-176

Health benefits are generated
By lower prices bus and subsidies for
walking and cycling



2ND BEST: SB1 = BUS FARE >0 SB2=BUS FARE >0 + NO SUBSIDIES WALK +CYCLE

	<i>Scenario</i>	<i>FB</i>	<i>SB1</i>	<i>%Δ from FB</i>	<i>SB2</i>	<i>%Δ from FB</i>
Welfare	<i>S0</i>	3 117	3 117	0,00 %	3 117	0,00 %
	<i>S1</i>	3 176	3 176	0,00 %	3 172	-0,13 %
	<i>S2</i>	3 272	3 272	0,00 %	3 232	-1,22 %
Access distance	<i>S0</i>	415	415	0,00 %	415	0,00 %
	<i>S1</i>	615	606	-1,46 %	615	0,00 %
	<i>S2</i>	618	607	-1,78 %	618	0,00 %
Car toll	<i>S0</i>	43	43	0,00 %	43	0,00 %
	<i>S1</i>	42	42	0,00 %	46	9,52 %
	<i>S2</i>	39	40	2,56 %	50	28,21 %
Bus fare	<i>S0</i>	6	6	0 NOK	6	0 NOK
	<i>S1</i>	-1	0	1 NOK	2	3 NOK

REDUCTION OF BUS STOPS AND WELFARE GAINS REMAIN UNDER SECOND BEST RESTICTIONS ON SUBSIDIES

DISCUSSION – NEXT STEPS

- More research is needed to disentangle internal from external health benefits.
- Effect of health benefits on the value of travel time savings.
- Relationship between pricing (bicycle subsidies) and infrastructure (cycleways) incentives to cycling.
- Extension to bike-sharing and integration bike-sharing – public transport.
- Accessibility issues for disabled people.
- Alternative ways of promoting health exercises (sports at work, at conferences) may be more efficient and may crowd out the health benefits of active mobility